Dupixent COPD denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent copd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Dupixent for COPD as Non-Formulary

A non-formulary denial means Dupixent (dupilumab) is not listed on UnitedHealthcare's preferred drug list for the benefit tier your plan uses, or it is excluded from the formulary for the COPD indication specifically. Formulary decisions are made at the plan level and often do not reflect individual clinical circumstances. You have a legal right to request an exception — and for a drug with an FDA-approved indication that your prescriber recommends, that exception process is well-established.

## Federal Appeal Rights

• ACA §2719 requires non-grandfathered health plans to offer internal appeals and external review. A formulary exclusion denial that has a clinical basis (not purely administrative) is eligible for external IRO review.
• ERISA §503 guarantees a full-and-fair internal review with a written reason for employer-sponsored plans.
• Internal appeal/exception request: typically must be filed within 180 days of denial notice.
• External review: generally available within 4 months of a final internal denial.
• Expedited exception: available when the standard timeline would seriously harm your health.

## Two Paths: Formulary Exception + Medical-Necessity Appeal

You should pursue both simultaneously:

Formulary Exception Request — UHC is required by federal rules to have a formulary exception process. Your prescriber files a statement that no formulary alternative is clinically appropriate for you. Key arguments: (a) formulary alternatives do not target the same biological pathway; (b) you have an inadequate response or contraindication to formulary alternatives (documented in chart); (c) dupilumab is the FDA-approved agent for your specific COPD endotype.

Medical-Necessity Appeal — even if granted as non-formulary, you may still need prior authorization. Run the medical-necessity documentation process in parallel (see the medical-necessity guidance on this site).

## What to Gather

1. List of formulary alternatives UHC proposed — request this in writing if not provided in the denial letter. 2. Clinical reason each alternative is inadequate — your prescriber should document why each proposed formulary substitute does not address your type-2 inflammatory COPD endotype. 3. Diagnosis and phenotype documentation — chart notes confirming COPD, eosinophil or biomarker data, exacerbation history. 4. Prescriber medical-necessity and exception letter — should cite the FDA-approved indication, applicable guideline organization recommendations, and specifically address why formulary alternatives are not therapeutically equivalent for your case. 5. UHC's formulary and exception policy — obtain the current document to ensure your request addresses every stated criterion.

## Criteria-Mapping Structure

| Exception Criterion | Supporting Evidence | |---|---| | No formulary alternative targets same pathway | Prescriber explanation of IL-4/IL-13 mechanism vs. alternatives | | Clinical trial of alternative not appropriate | Chart documentation of inadequate response or clinical reason | | FDA approval for requested drug in this indication | Reference to current prescribing label indication section |

If UHC denies the exception, escalate immediately to external IRO review. IRO decisions are binding on the insurer.